Fig. 8: Graphic summary highlighting the impact of liver-derived ARSA on sulfatide and lysophospholipid metabolism in liver lipid rafts, the reduction in LPC and LPA levels in the blood, and how the reduced LPA relieves skeletal muscle insulin resistance. | Nature Communications

Fig. 8: Graphic summary highlighting the impact of liver-derived ARSA on sulfatide and lysophospholipid metabolism in liver lipid rafts, the reduction in LPC and LPA levels in the blood, and how the reduced LPA relieves skeletal muscle insulin resistance.

From: Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control

Fig. 8: Graphic summary highlighting the impact of liver-derived ARSA on sulfatide and lysophospholipid metabolism in liver lipid rafts, the reduction in LPC and LPA levels in the blood, and how the reduced LPA relieves skeletal muscle insulin resistance.

LPA lysophosphatidic acid, LPC lysophosphatidylcholine. Created with BioRender.com.

Back to article page